Registration of “Document E” and clearance of admission prospectus related to the proposed cross-border of Topotarget into BioAlliance Pharma

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced announces today that on 26 May 2014, the Autorité des Marchés Financiers has registered the « Document E » (n° E.14-034) and granted clearance on the “Prospectus d’admission” (n° 14-232) related to the proposed cross-border merger of Topotarget A/S into BioAlliance Pharma SA.

The “Document E” and the “Prospectus d’admission” are available, free of charge upon request, at the registered office of BioAlliance Pharma and on its website, in French version and in English version -for information purposes only- (www.onxeo.com), as well as on the website of the Autorité des Marchés Financiers (www.amf-france.org).

140528EN_Document E